The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and ...
Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...
Zacks.com on MSN1h
ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?AbbVie ABBV continued its acquisition spree with the announcement of a definitive agreement to acquire private biotech Nimble ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback